var data={"title":"Lubiprostone: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Lubiprostone: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/209754?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=lubiprostone-patient-drug-information\" class=\"drug drug_patient\">see &quot;Lubiprostone: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2609746\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Amitiza</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2609750\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Chloride Channel Activator;</li>\n      <li>\n        Gastrointestinal Agent, Miscellaneous</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2610838\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic idiopathic constipation: </b> Oral: 24 mcg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Irritable bowel syndrome with constipation:</b> Females &ge;18 years: Oral: 8 mcg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Opioid-induced constipation:</b> Oral: 24 mcg twice daily</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2610839\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2610840\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2610841\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Mild hepatic impairment (Child-Pugh class A):</b>  No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Moderate hepatic impairment (Child-Pugh class B): </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Chronic idiopathic constipation or opioid-induced constipation:</i> Initial: 16 mcg twice daily; may increase to 24 mcg twice daily if tolerated and an adequate response has not been obtained with lower dosage.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Irritable bowel syndrome with constipation:</i> No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Severe hepatic impairment (Child-Pugh class C):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Chronic idiopathic constipation or opioid-induced constipation:</i> Initial: 8 mcg twice daily; may increase to 16 to 24 mcg twice daily if tolerated and an adequate response has not been obtained with lower dosage.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Irritable bowel syndrome with constipation:</i> Initial: 8 mcg once daily; may increase to 8 mcg twice daily if tolerated and an adequate response has not been obtained at lower dosage.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2610846\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Amitiza: 8 mcg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Amitiza: 24 mcg [contains fd&amp;c red #40, fd&amp;c yellow #10 (quinoline yellow)]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2609748\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2610844\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer with food and water. Swallow whole; do not break or chew. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2609751\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic idiopathic constipation:</b> Treatment of chronic idiopathic constipation in adults</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Irritable bowel syndrome with constipation:</b> Treatment of irritable bowel syndrome (IBS) with constipation in women &ge;18 years</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Opioid-induced constipation:</b> Treatment of opioid-induced constipation in adults with chronic noncancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (eg, weekly) opioid dosage escalation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2609759\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (2% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (8% to 29%; dose related; males: 8%; older adults: 19%), diarrhea (7% to 12%)</p>\n    <p style=\"text-indent:0em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Edema (&le;3%), chest discomfort (&le;2%), chest pain (&le;2%), peripheral edema (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness (3%), fatigue (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal pain (4% to 8%), flatulence (4% to 6%), abdominal distention (3% to 6%), abdominal distress (3%), loose stools (&le;3%), vomiting (&le;3%), dyspepsia (&le;2%), xerostomia (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Dyspnea (&le;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Anorexia, anxiety, arthralgia (Anton 2017), back pain (Anton 2017), bloody diarrhea (Anton 2017), bowel urgency, constipation, cough, decreased appetite, decreased serum potassium, depression, diaphoresis, dysgeusia, eructation, erythema, fecal impaction, fecal incontinence, fibromyalgia syndrome, frequent bowel movements, gastritis, gastroesophageal reflux disease, gastrointestinal disease, hyperhidrosis, hypersensitivity reaction (including skin rash, swelling, throat tightness), hypotension, increased serum ALT, increased serum AST, influenza, ischemic colitis, joint swelling, lethargy, malaise, muscle cramps, muscle spasm, myalgia, neck pain (Anton 2017), pain, palpitations, pharyngolaryngeal pain, pollakiuria, rectal hemorrhage, respiratory tract infection (Anton 2017), syncope, tachycardia, tremor, urinary tract infection, weakness, weight gain</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2609755\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Known or suspected mechanical gastrointestinal (GI) obstruction</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2609756\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dyspnea: Has been observed with use; often described as chest tightness and difficulty in taking a breath; generally occurs as an acute onset (within 30 to 60 minutes following the first dose) and resolves within a few hours; however, has been frequently reported with subsequent dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Nausea: Nausea may occur; administer with food to reduce symptoms.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Syncope/hypotension: May occur (some resulting in hospitalization) and generally resolved following discontinuation or prior to the next dose; reoccurrence has been reported with subsequent doses. Most cases occurred when taking 24 mcg twice daily, within an hour after the first dose or subsequent doses, or during concomitant use of medications known to decrease blood pressure.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diarrhea: Avoid use in patients with severe diarrhea.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal obstruction: Symptoms of mechanical GI obstruction should be evaluated before prescribing this medicine; use is contraindicated in patients with bowel obstruction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Patients with moderate-to-severe hepatic impairment (Child-Pugh class B or C) have higher systemic drug exposure; dosage adjustment may be recommended, depending on the indication and severity of hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Males: Not approved for use in males with irritable bowel syndrome with constipation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>\n          <b>Other warnings/precautions</b>:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Efficacy of lubiprostone in the treatment of opioid-induced constipation in patients taking diphenylheptane opioids (eg, methadone) has not been established.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299620\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6221379\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=10195&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Methadone: May diminish the therapeutic effect of Lubiprostone.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2609752\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2609753\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15788822\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if lubiprostone or its active metabolite are present in breast milk. The manufacturer recommends that caution be exercised and breastfeeding infants be monitored for diarrhea when administering lubiprostone to breastfeeding women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2610843\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Take with food and water to decrease nausea.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2610828\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">A chloride channel activator that acts locally on the apical membrane of the gastrointestinal tract to increase intestinal fluid secretion and improve fecal transit. This action bypasses the antisecretory effects of opiates, which suppress secretomotor neuron excitability.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2610830\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Systemic: Parent drug: Poor (below levels of detection); Active metabolite (M3): Low</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Minimal beyond GI tissue</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: ~94%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Rapid and extensive within stomach and jejunum by carbonyl reductase to M3 (active metabolite) and others</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Minimal</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: M3: 0.9 to 1.4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: M3: ~1.1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Parent drug and M3: Feces (trace amounts)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3422176\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Amitiza Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">8 mcg (60): $445.32</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">24 mcg (60): $445.32</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14721643\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Amitiza (BB, CH, GB, JP);</li>\n      <li>Lubilax (BD);</li>\n      <li>Lubistone (BD);</li>\n      <li>Lubowel (IN);</li>\n      <li>Modulex (CO)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Amitiza (lubiprostone) [prescribing information]. Deerfield, IL: Takeda Pharmaceuticals America; August 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anton C. Adverse effects of laxatives: update. Wolters Kluwer Adverse Drug Reaction Bulletin. 2017;303.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Johanson JF and Ueno R, &ldquo;Lubiprostone, a Locally Acting Chloride Channel Activator, In Adult Patients With Chronic Constipation: A Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate Efficacy and Safety,&rdquo; <i>Aliment Pharmacol Ther</i>, 2007, 25(11):1351-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lubiprostone-drug-information/abstract-text/17509103/pubmed\" target=\"_blank\" id=\"17509103\">17509103</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 10195 Version 98.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F2609746\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F2609750\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F2610838\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F2610839\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F2610840\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F2610841\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F2610846\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F2609748\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F2610844\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F2609751\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F2609759\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F2609755\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F2609756\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299620\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6221379\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F2609752\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F2609753\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F15788822\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F2610843\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F2610828\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F2610830\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F3422176\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F14721643\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/10195|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=lubiprostone-patient-drug-information\" class=\"drug drug_patient\">Lubiprostone: Patient drug information</a></li></ul></div></div>","javascript":null}